Brought to you by 
Bayer receives global license to Compugen’s cancer immunotherapeutics
Aug 2013
Executive Summary
For the second time, Compugen Ltd. (Israeli drug discovery company that trades on Nasdaq) and Bayer HealthCare LLC are teaming up. This time, the Big Pharma is getting global rights to Compugen’s cancer antibodies targeting two immune checkpoint regulators that are critical in immunosuppression.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer receives global license to Compugen’s cancer immunotherapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice